Pharma Pulse 7/8/25: The Administration’s Biggest Impacts on Pharma; The Rising Stakes of Patient Retention in Clinical Trials
The Administration’s Biggest Impacts on Pharma
In an interview with Pharmaceutical Executive, William Soliman, CEO, Accreditation Council for Medical Affairs, discussed how tariffs, changes to vaccine policy at HHS, and accelerated drug approvals are significantly impacting the pharmaceutical industry, while emphasizing that medical affairs teams must improve governance and preparedness in response to increased scrutiny and compressed launch timelines.
The Rising Stakes of Patient Retention in Clinical Trials
In an interview with Applied Clinical Trials, Heather Horville, solutions consultant, Greenphire, emphasized that rising financial and logistical burdens are making patient retention in clinical trials increasingly difficult—jeopardizing timelines and data quality—and highlighted the need for early planning, tailored site selection, and enhanced patient support services to improve outcomes.
When Less Is More: Addressing Polypharmacy in High-Risk Populations
Andrew Esch, MD, MBA, director, Palliative Care Program Development at the Center to Advance Palliative Care, emphasized that digital tools and evolving deprescribing guidelines are helping pharmacists combat polypharmacy in high-risk populations, but structural barriers, reimbursement gaps, and social determinants of health continue to hinder progress—underscoring the need for systemic reforms to make deprescribing a routine part of patient-centered care.
Q&A: Expert Highlights Importance of Trusted Sources for Vaccine Information
In an interview with Drug Topics, Laura Knockel, PharmD, BCACP, emphasized the urgent need for health care providers and patients to rely on trusted, evidence-based sources for vaccine information amid a shifting policy landscape—warning that misinformation and abrupt changes in recommendations could threaten insurance coverage, access, and public health, particularly for vulnerable populations.
Baxter Taps a New CEO as it Emerges from Years-Long Restructuring
Baxter has named Andrew Hider as its next CEO amid a major restructuring effort, bringing in the former ATS leader to steer the company’s next phase of growth after divesting key business units and refocusing on innovation and long-term performance.
How Industry Stakeholders View Medicare Advantage Expansion for Patients with Kidney Disease
July 7th 2025A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
